Rifafit 400mg Tablet is an antibiotic medicine commonly prescribed for the treatment of tuberculosis (TB) and some other bacterial infections. It works by killing or stopping the growth of bacteria, which helps in clearing the infection. This medicine is usually given in combination with other anti-TB drugs to prevent resistance and ensure effective treatment.
Uses of Rifafit Tablet
-
Tuberculosis (TB)
-
Other bacterial infections as advised by your doctor
Benefits of Rifafit Tablet
-
Helps eliminate the bacteria that cause TB
-
Reduces symptoms such as cough, fever, and fatigue
-
Prevents the infection from spreading further
-
Improves recovery when taken with other anti-TB medicines
Common Side Effects
Most side effects are mild and manageable. Inform your doctor if they persist:
-
Nausea, vomiting, stomach upset
-
Diarrhea or abdominal pain
-
Headache, dizziness, weakness
-
Skin rash, itching
-
Orange-red discoloration of urine, sweat, or tears (harmless but common)
-
Liver enzyme changes (requires regular monitoring)
How to Use
-
Take the dose as prescribed by your doctor.
-
Swallow whole with water, preferably on an empty stomach.
-
Always take it in combination with other TB medicines.
-
Do not stop treatment early, even if you feel better.
How It Works
Rifafit 400mg Tablet belongs to the rifamycin class of antibiotics. It blocks essential bacterial enzymes required for survival, thereby preventing bacterial growth and helping the body fight infection.
Safety Advice
-
Alcohol: Avoid, as it can increase liver-related side effects.
-
Pregnancy: Use only if prescribed by your doctor.
-
Breastfeeding: Consult your doctor before use.
-
Driving: May cause dizziness; avoid driving if affected.
-
Liver disease: Use with caution; dose adjustment and monitoring may be needed.
-
Kidney disease: Inform your doctor; dose adjustment may be necessary.
Missed Dose
Take it as soon as you remember. If it’s almost time for your next dose, skip the missed one. Do not take two doses at the same time.
Reviews
There are no reviews yet.